In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

2011 Scrip 100: Fred Hassan - Challenge 2020

This article was originally published in Scrip

Executive Summary

Ask many in the financial community about life sciences in the next decade, and one hears "it's going to be different, right?" The tone is often sceptical. The investing environment in life sciences has turned unfavourable in recent years. At financial gatherings in New York and elsewhere, one hears how investment funds from sectors such as energy are "in", and how funds representing life sciences are "out". They have a point. The stock indices' – whether it is big pharma or other pharma groupings – show 11 years of no progress, although not unlike the S&P 500.

You may also be interested in...



CEO CORNER: A new blog feature with Fred Hassan

I have returned from the PhRMA Annual Meeting in San Diego. My recent book was handed out to all registrants of the meeting and I got to hear from many of them. I appreciate feedback. And the takeaways from my book are the same as my own personal playbook.

Lessons in Lifecycle Management: Successors, Flankers and Toppers

Successors, flankers and toppers are product lifecycle management (LCM) categories used by pharma executives, although they may be referred to differently by other companies.

Fred Hassan: Getting traction with lifecycle management

Early in my career, I learned the essential principle of product lifecycle management (LCM): "Do LCM because you create value for the patient or the customer – not just because you want to get more profit out of each molecule."

Topics

Related Companies

UsernamePublicRestriction

Register

SC011286

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel